Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Podsumowanie

This protocol demonstrates real-time recording of full dose-response relationships for agonist-induced GPCR activation from a single cell layer grown on a single microelectrode using label-free impedance measurements. The new dosing scheme significantly increases throughput without loss in time resolution.

Streszczenie

Label-free impedance-based assays are increasingly used to non-invasively study ligand-induced GPCR activation in cell culture experiments. The approach provides real-time cell monitoring with a device-dependent time resolution down to several tens of milliseconds and it is highly automated. However, when sample numbers get high (e.g., dose-response studies for various different ligands), the cost for the disposable electrode arrays as well as the available time resolution for sequential well-by-well recordings may become limiting. Therefore, we here present a serial agonist addition protocol which has the potential to significantly increase the output of label-free GPCR assays. Using the serial agonist addition protocol, a GPCR agonist is added sequentially in increasing concentrations to a single cell layer while continuously monitoring the sample's impedance (agonist mode). With this serial approach, it is now possible to establish a full dose-response curve for a GPCR agonist from just one single cell layer. The serial agonist addition protocol is applicable to different GPCR coupling types, G_q G_i/0 or G_s and it is compatible with recombinant and endogenous expression levels of the receptor under study. Receptor blocking by GPCR antagonists is assessable as well (antagonist mode).

Wprowadzenie

This report presents a detailed description of a serial addition protocol developed for the quantification of ligand-induced G protein-coupled receptor (GPCR) activation in adherently grown cells by label-free impedance measurements. G protein-coupled receptors (GPCRs) are involved in a multitude of physiological functions and human diseases¹. Because of this and their good accessibility at the cell surface, GPCRs are one of the most important drug targets. This assessment is reflected in an estimated number of ~700 approved drugs targeting GPCRs, equivalent to a ~35% share on all marketed drugs².

The development of new drugs comprises two central processes: (i) the identification and functional characterization of biological target molecules, and (ii) the discovery of new lead substances and their development into administrable drugs. In both processes, efficient methods are required to quantitatively evaluate drug-target interactions and the subsequent biological downstream response. Different stages of the pre-clinical drug development process make use of different methods of analysis ranging from biomolecular interaction studies between drug and target, over functional studies on cells in culture, to experiments on excised organ material or whole animals. Both, physiological significance and biological complexity increase from the former to the latter³. Although it is the overall goal to minimize animal experiments, pharmacological studies using isolated organs from laboratory animals or even whole animals are regarded inevitable to comprehensively characterize new drug candidates. In terms of analytical readout, organ pharmacology studies provide a distal, integrative "holistic" functional response of highest physiological relevance. A drawback of such experiments is that they are not compatible with high throughput screening for technical as well as ethical reasons and have been largely substituted by studies based on in vitro cell culture⁴.

Methods to quantify GPCR activation in cell cultures include different label-based chemical assays, which specifically detect second messengers, phosphorylation state of downstream signaling proteins, transcriptional activation via certain transcription factors or ligand-induced intracellular receptor trafficking^4,5. A drawback of such label-based assays is the necessity to label the cells with potentially harmful dyes or radioactive markers. This often requires running the assay as an endpoint-determination for an exposure time that has to be specified a priori. Using label-based endpoint assays suffers from this very limited and biased timing of the experiment and the risk that chemical labels and probes may interfere with the regular cell physiology – potentially unnoticed by the experimenter.

In recent years, label-free assays for monitoring GPCR activation have emerged, like impedance-based techniques or optical methods applying resonant waveguide gratings^5,6. Labelling of the cells is experimentally not required with these approaches. As these physical readouts operate on low amplitude signals, such methods are considered non-invasive, they allow for continuous cell monitoring potentially in real time and the observation time is only limited by the cell culture not by the readout. Similar to readouts from whole organs, label-free approaches commonly report on holistic cell responses, far downstream of receptor activation when integration along the entire signaling network leads to time-dependent but rather unspecific changes in cell morphology or mass redistribution. Whereas impedance-based assays measure the dielectric signature of changes in cell shape^7,8, measurements using resonant waveguide gratings are sensitive to changes in refractive index at the cell-substrate interface arising from dynamic mass redistribution (DMR)⁹. The integrative character makes label-free methods extremely sensitive to receptor-mediated events regardless of the type(s) of G protein (G_q, G_i/0, G_s, G_12/13) or β-arrestin involved in the signaling cascade⁶ and well-suited for endogenous expression levels of the receptor.

In a standard label-free impedance-based assay the cells are adherently grown in multi-well plates with coplanar gold-film electrodes deposited on the bottom of each well¹⁰. These electrode arrays are connected to an impedance analyzer and the cell responses to an experimental stimulus are recorded from individual wells by time-resolved impedance readings. In a typical GPCR assay a ligand is added in individually different concentrations to each individual well. The ligand-induced changes in the impedance time course are then analyzed with respect to characteristic curve features such as maximum signal change, area under the curve, signal change within a given time interval or slope of the curve at a specified time point, in order to quantify the ligand's potency and efficacy¹¹.

The cost of the electrode arrays may limit the application of this technique in high throughput screening (HTS) campaigns. Moreover, with increasing numbers of samples to be followed in parallel, the number of individual measurements increases and thereby reduces the available time resolution for each well gradually - even for state of the art multichannel recordings. Under such conditions fast and transient cell responses may escape the measurement. In addition, the conventional one well – one concentration approach imposes a significant time and cost factor on perfused organ-on-chip or body-on-chip developments with respect to their suitability in ligand-GPCR interaction analysis.

For this reason, we developed a stepwise dosing protocol that enables recording of full dose-response curves of ligand-induced GPCR activation in cultured cell monolayers by continuously monitoring the impedance of a single well while the agonist concentration is increased stepwise. The serial agonist addition protocol significantly increases throughput per well from one concentration to 10 or more concentrations, as shown on the current example of human U-373 MG cells, which endogenously express the histamine 1 receptor (H1R). Thus, the method has the potential to significantly improve throughput in label-free dose-response studies, while the time resolution is retained at the instrumental maximum.

Access restricted. Please log in or start a trial to view this content.

Protokół

1. Cell seeding on electrode arrays

NOTE: Selection of electrode layout is a trade-off between sensitivity and number of cells under study. The smaller the electrode, the more sensitive is the measurement but the smaller is the number of cells under study. For cells showing strong impedance fluctuations over time under baseline conditions, bigger or interdigitated electrodes are preferable.

1. Pre-warm all solutions needed for standard cell passaging and seeding in a 37 °C water bath. For assays with human U-373 MG cells it takes: phosphate buffered saline (PBS) without calcium and magnesium, 0.05% (w/v) trypsin, cell culture medium (Eagle's Minimum Essential Medium (EMEM) supplemented with 5% (v/v) fetal calf serum (FCS), 2 mM L-glutamine and 100 µg/mL penicillin/streptomycin).
2. Rinse the cell layer of the stock culture grown on the bottom of conventional cell culture flasks or dishes with PBS twice.
3. Remove the PBS, add the trypsin solution (1 mL for 25 cm²) and let the cells incubate at 37 °C for 5 min (applies to U-373 MG cells).
4. Control for complete detachment of the cells from the bottom of the growth substrate by microscopy.
5. Stop the trypsin reaction as soon as the cells are completely detached by adding 9 mL of cell culture medium per 1 mL of trypsin to the cell suspension. Carefully rinse remaining cells from the bottom of the cell culture substrate by pipetting the suspension over the substrate.
6. Collect the cell suspension with a pipette and transfer it to a centrifugation tube (15 mL or 50 mL tube).
7. Spin down the cells by centrifugation at 110 x g for 10 min at room temperature.
8. Carefully remove the supernatant and thoroughly re-suspend the cell pellet in culture medium before counting the cells (e.g. by using a hemacytometer for phase contrast microscopes and manual counting).
9. Adjust the cell suspension to the desired cell density. For experiments with U-373 MG cells, use 100 000 cells/cm² to grow a confluent cell layer within 48 h. This translates to a cell density of 200 000 cells/mL for 8-well electrode arrays with a growth area of ~0.8 cm² and a well volume of 400 µL.
   NOTE: For reproducible GPCR activation experiments, cells should be grown to confluent monolayers on the electrode arrays. To ensure proper receptor expression on the cell surface, cells should be seeded at least 36 h before performing the experiment. Testing different cell densities for cell seeding is often meaningful to identify the best experimental conditions.
10. Add the cell suspension to the wells of the electrode array and let the sells settle down at room temperature for 10 – 15 min in order to ensure homogenous distribution of cells on the bottom of the wells.
11. Grow cells for at least 36 h in a standard cell culture incubator with 5% CO₂ (dependent on medium type) at 37 °C and humidified atmosphere. Change cell culture medium 24 h prior to the experiment.
12. On the day of the experiment, inspect the cell layers on the electrode arrays by (phase contrast) microscopy to ensure complete coverage of electrodes with cells.

2. Equilibration of cells in serum-free medium

1. Pre-warm serum-free medium, in this study: Leibovitz's L15 medium.
2. Remove cell culture medium from cells grown on electrode arrays and replace by pre-warmed serum-free medium. Use 200 µL for 8-well format electrode arrays, and 150 µL for 96-well electrode arrays.
3. Let the cells equilibrate in serum-free medium at 37 °C for at least 2 h. The equilibration time strongly depends on the cell type. For example, U-373 MG cells need 2 h, CHO cells need 4 h, BAEC may require overnight equilibration in L-15 medium.
   NOTE: L-15 medium is CO₂ independent and requires a CO₂-free atmosphere. For equilibration in L-15 set the incubator to 0 % CO₂. Equilibration can be monitored by impedance readings, which we recommend to do for the first experiments.

3. Monitoring cell equilibration with impedance readings

1. Place the electrode array into the connecting array holder of the impedance analyzer.
2. Ensure proper low impedance contact between electrodes and impedance analyzer. This check is individually different for different instruments.
   NOTE: If the instrument fails to make connection to the electrodes, open the contact clamp again, readjust the electrode array for proper positioning inside the holder and retry.
3. Select electrode type and/or multi-well format from the user interface of the software.
4. Set up the measurement parameters. Different options are available.
   NOTE: To select the most sensitive AC frequency, we refer to the literature and instrument manuals as it depends on electrode layout and cell type under study. Typically, the sensing frequency is in the range of 4 kHz – 50 kHz. Here, U-373 MG cells were grown on circular working electrodes of 250 µm diameter and they were monitored at an AC frequency of 12 kHz.
   1. If single and multiple frequency data acquisition modes are available, select the single frequency mode to ensure maximum time resolution. The measurement will be performed at this single frequency. For the most widely spread instruments, there is a number of pre-set frequencies along the available frequency window.
   2. If the number of wells under study is low or time resolution is not critical, select multiple frequency recordings instead. Impedance readings at a specified number of frequencies will be recorded for every well for later in-depth analysis.
      NOTE: The time resolution decreases with increasing number of frequencies recorded per well and increasing number of wells. The options for frequency and data acquisition mode selection vary with instrument type and version.
5. Start acquisition of time course data.
6. Follow the cell layer impedance (at least 2 h) until the impedance has stabilized. In the meantime, prepare the agonist solutions.
7. When the cell layers have reached a stable impedance level, either (i) proceed to the serial agonist addition within the same experiment or (ii) terminate data acquisition and start a new dataset for monitoring agonist-induced receptor activation.

4. Preparation of agonist solutions for experiments in agonist mode

1. Calculate the concentration of agonist solutions as needed for each step of serial dosing according to equation (1). n ranges from 1 to the total number of serial additions i. x denotes concentration and volume in the well at step n. y denotes concentration and volume of the "solution-to-be-added" in step n.

NOTE: Consider the number of replicates and calculate the total volume of "solution-to-be-added" for each concentration step. Results of a typical calculation are given in Tables 1-4. It takes a general idea about the agonist concentration range to be studied as the range defines the concentrations and number of portions to be administered during serial addition. Using the serial agonist addition protocol the agonist concentration is increased stepwise. Therefore, the amount of agonist already in the well when the next dose is added has to be taken into account. When the number of agonist molecules already present in the well is n_x = c_x ∙V_x (with the current concentration c_x and volume V_x) and the number of molecules in the well after the next addition is n_x+y, the number of molecules to be added n_y is determined by the concentration c_y and volume V_y of the solution to be applied to the well (n_y = c_y ∙ V_y). After adding a portion of agonist, the new amount of agonist molecules in the well is: c_x+y ∙ V_x+y = c_x ∙ V_x + c_y ∙ V_y. This calculation applies for each subsequent step. Because of the interdependence of agonist concentration in the well and the amount of agonist in the portions to be added with each step, it is important to define final concentrations after each step in advance.

Mode 1: The volume in the well will increase with each step as liquid is continuously added.
Using this mode and an 8-well format, use V_x1 = 200 µL and V_{y1 ….} V_yi = 30 µL.

Mode 2: The volume in the well is constant as the volume added with each step is removed just before the subsequent addition.
Using this mode and a 96-well format, use V_x1 = 150 µL and V_{y1 ….} V_yi = 75 µL.

2. Print the data sheet with the total volume per concentration and detailed instructions for pipetting.
3. Prepare all solutions in the required amount. Make all agonist solutions in the same serum-free medium as used for equilibration of the cells.
   CAUTION: Histamine dihydrochloride is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200). Histamine causes skin irritation, serious eye irritation, may cause an allergic skin reaction, allergy, asthma symptoms or breathing difficulties if inhaled and may cause respiratory irritation. Please consider the safety data sheet.
   NOTE: Make agonist solutions as fresh as possible. Stability of agonists in solution may vary considerably. Store solutions at 4 °C or below until use in the experiment. For some molecules additional stabilizing additives, like BSA when using peptide-based or lipid-based molecules, may be considered to prevent adsorption to the walls of wells and tubes.
4. If performing the experiment in 96-well format, transfer solutions to a conventional 96-well plate (no electrodes) and use an 8- (or 12-) channel pipet for quick liquid transfer to the electrode array.

5. Preparation of agonist solutions for experiment in antagonist mode

NOTE: Prepare the antagonist solution(s) with the concentration to be applied throughout. Volume and concentration of antagonist solution depend on the mode of agonist addition (1 or 2). Examples for experiments in 8-well or 96-well format in addition mode 2: (A) 8-well format (V_x1 = 200 µL, V_Antagonist = 200 µL); (B) 96-well format (V_x1 = 150 µL, V_Antagonist = 75 µL).

1. Calculate the concentration of each agonist solution needed for each step of serial dosing as described in step 4.1.
2. Make all agonist solutions in the same serum-free medium as used for equilibration of the cells and add the antagonist at the same final concentration as planned for the respective wells in the experiment.
   NOTE: In this case the histamine stock solution (10 mM) is prepared in L-15 medium. When agonists are dissolved in other solvents (e.g., dimethyl sulfoxid (DMSO), ethanol) a solvent control should be included to account for the increasing solvent load with each step of addition.

6. Performing the serial addition protocol in agonist mode

1. Start data acquisition as described in steps 3.1 – 3.5.
2. Pre-warm the agonist solutions prior to use by placing them in the incubator about 10 – 15 min before addition.
   NOTE: When using thermo-labile substances, the solutions should not be kept at 37 °C for too long. If pre-warming for 10 – 15 min is considered critical, bring solutions to 37 °C shortly before addition in a water bath.
3. Run the agonist serial dosing dependent on the selected addition mode. Following mode 1 the total volume in the well increases with each addition of the next dose. In mode 2 the same volume which is added with each step is also removed again just before adding the next higher dose.
   NOTE: Time needed for equilibration of the cell layer in between two subsequent agonist doses depends on the cells' response time. An initial experiment in parallel mode (one well – one concentration) reveals (i) cell response times for different agonist concentrations and (ii) the most sensitive curve parameter (e.g., impedance maximum, impedance after time x).

A: Mode 1 / 8-well format

1. Add 30 µL of the first solution with the lowest concentration of agonist to the cells that were equilibrated in 200 µL of serum-free medium.
2. Let the cells respond and equilibrate for the pre-defined period of time (e.g., 15 min).
3. Add 30 µL of the second solution with the next higher concentration.
4. Repeat steps 6.3.1-6.3.3 with the third, fourth, and so on, agonist solution.
   NOTE: Working with 10 concentration steps will result in a total volume of 500 µL in the end of the experiment, which is just below the maximum applicable volume of these wells of ~ 550 µL.

B: Mode 2 / 96-well format

NOTE: Pause data acquisition during each liquid handling step (addition/removal) via the impedance instrument's software when running experiments in 96-well format. The more elaborate liquid handling may interfere with data acquisition. Use a multi-channel pipette.

1. Pause data acquisition.
2. Add 75 µL of the first solution with the lowest concentration of agonist to the cells that were equilibrated in 150 µL of serum-free medium.
3. Resume data acquisition.
4. Let the cells respond and equilibrate for the pre-defined period of time (e.g., 15 min).
5. About 1 – 2 min before the regular equilibration time ends, pause the measurement and remove 75 µL from each well.
   NOTE: The time point at which solution should be removed depends on the number of wells monitored in parallel and the pipetting speed. Time needed for removal of the solutions should not exceed the time between subsequent steps.
6. Add 75 µL of the second solution with the next higher concentration and resume the measurement.
7. Repeat steps 6.3.8-6.3.10 with the third, fourth, and so on, agonist solution.

7. Performing the serial addition protocol in antagonist mode

1. Start the measurement as described in steps 3.1 – 3.5.
2. During equilibration of the cell layers, prepare antagonist solution (e.g., 200 µL of 1.5 µM diphenhydramine hydrochloride in L15 medium).
   CAUTION: Diphenhydramine hydrochloride has potential acute health effects. It is harmful if swallowed or inhaled, may cause eye and skin irritation. It may cause respiratory and digestive tract irritation. Please consider the safety data sheet.
3. Pre-warm the antagonist and agonist solutions by placing them in the incubator about 10 – 15 min before addition to the cell cultures (cf. 6.2). If antagonist-free wells are included in the assay as well, also pre-warm serum-free medium.
4. Add the antagonist solution to the designated wells. Let the cells equilibrate with antagonist for 15 – 20 min. If antagonist-free wells are included, add the same volume of serum-free medium to these wells.
5. According to antagonist addition in mode 2, remove solution from the wells
   (A) 8-well format (200 µL)
   (B) 96-well format (75 µL)
6. Run the agonist addition sequence as described in step 6.3.

8. Data export and analysis

1. Export data using the impedance instrument's software in order to convert all recorded data from proprietary into common data formats (e.g., csv). This step allows for data re-organization and presentation with other software packages.
2. Load the csv-formatted data to scientific data analysis software.
3. Normalize impedance values by subtracting the impedance of the last data point before the first addition of agonist solution and by setting the time of addition to t = 0. Plot the time course of normalized impedance.
4. Plot the individual time courses and identify the maxima in impedance after each addition step. Compose a data sheet with these values.
5. Plot the values of maximum (or minimum, if applicable) impedance changes as a function of agonist concentration. This can be done for individual wells or for the averages (mean ± SD).
6. Use a data fitting routine to determine half-maximal effective concentrations (EC₅₀) and maximum response (E_Max) by using the four parameter logistic model (equation 2):

NOTE: c indicates the agonist concentration, A₁ is the minimum and A₂ is the maximum asymptote of the sigmoidal dose-response curve (A₂ = E_Max). EC₅₀ is the concentration at the inflection point of the curve, and n corresponds to the Hill slope.

Access restricted. Please log in or start a trial to view this content.

Wyniki

A typical scheme for preparing the various agonist solutions is shown for an experiment using 8-well electrode arrays with histamine as agonist in Tables 1-4. Table 1 and Table 2 present volumes and concentrations for an experiment using addition mode 1 (cf., Figure 1), while Table 3 and Table 4 present volumes and concentrations for an experiment following addition mode 2 (...

Access restricted. Please log in or start a trial to view this content.

Dyskusje

This protocol describes a method for label-free impedance measurements to determine the dose-response relationship of agonist-induced GPCR activation in absence or presence of specific antagonists for the same receptor. The proof of concept of this method was presented in a recent publication¹². To our knowledge it is the first study describing the establishment of a full dose-response curve of agonist-mediated GPCR activation using a single cell layer in vitro. The approach inevitably requires th...

Access restricted. Please log in or start a trial to view this content.

Materiały

Name	Company	Catalog Number	Comments
Bürker counting chamber	Marienfeld (Lauda-Königshofen, Germany)	640210
cell culture flasks 25 cm2	Greiner bio-one (Frickenhausen, Germany)	690175
Cell incubator (Heraeus Function Line BB15)	Thermo Scientific (Darmstadt, Germany)	\
Centrifuge (Heraeus 1S-R)	Thermo Scientific (Darmstadt, Germany)	\
Diphenhydramine hydrochloride	Sigma Aldrich (Taufkirchen, Germany)	D3630
Eagle's Minimum Essential Medium with 4.5 g/L D-Glucose and 2.2 g/L NaHCO3	Sigma Aldrich (Taufkirchen, Germany)	D5671
Impedance Instrument (ECIS Zθ)	Applied BioPhysics Inc. (Troy, NY, USA)	\
8-well electrode Arrays (8W1E PET)	Applied BioPhysics Inc. (Troy, NY, USA)	\	PET base with 0.049 mm2 working electrode and ~50 mm2 counter electrode (gold)
96-well electrode arrays (96W1E+ PET)	Applied BioPhysics Inc. (Troy, NY, USA)	\	PET base with two electrodes (gold) with 0.256 mm2 total electrode area
Fetal calf serum (FCS)	Biochrom (Berlin, Germany)	S0615
Histamine dihydrochloride	Carl Roth (Karlsruhe, Germany)	4017.1
Laminar flow hood (Herasafe, KS 12)	Thermo Scientific (Darmstadt, Germany)	51022515	class II safety cabinet
Leibovitz' L-15 medium	Thermo Scientific (Darmstadt, Germany)	21083-027
L-glutamine	Sigma Aldrich (Taufkirchen, Germany)	G7513
Micropipette large (100 - 1000 µL)	Brandt (Wertheim, Germany)	704780
Micropipette large (20 - 200 µL)	Brandt (Wertheim, Germany)	704778
Microscope (phase contrast, Nikon Diaphot)	Nikon (Düsseldorf, Germany)
Penicillin/streptomycin	Sigma Aldrich (Taufkirchen, Germany)	P0781
Phosphate buffered saline (PBS)	Sigma Aldrich (Taufkirchen, Germany)	D8537
Pipette, serological	Greiner bio-one (Frickenhausen, Germany)	607 180
Pipettor (accu-jet pro)	Brandt (Wertheim, Germany)	26300
Trypsin	Sigma Aldrich (Taufkirchen, Germany)	T4174	in PBS with 1 mM EDTA
Tube, 15 mL	Greiner bio-one (Frickenhausen, Germany)	188 271
Tube, 50 mL	Greiner bio-one (Frickenhausen, Germany)	210 261
U-373 MG cells	ATCC (Rockville, MD, USA)	ATCC HTB-17
water bath (TW21)	Julabo (Seelbach, Germany)	\